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Abstract: The adaptive optics scanning light ophthalmoscope (AOSLO) allows 
visualization of microscopic structures of the human retina in vivo. In this 
work, we demonstrate its application in combination with oral and intravenous 
(IV) fluorescein angiography (FA) to the in vivo visualization of the human 
retinal microvasculature. Ten healthy subjects ages 20 to 38 years were 
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imaged using oral (7 and/or 20 mg/kg) and/or IV (500 mg) fluorescein. In 
agreement with current literature, there were no adverse effects among the 
patients receiving oral fluorescein while one patient receiving IV fluorescein 
experienced some nausea and heaving. We determined that all retinal 
capillary beds can be imaged using clinically accepted fluorescein dosages and 
safe light levels according to the ANSI Z136.1-2000 maximum permissible 
exposure. As expected, the 20 mg/kg oral dose showed higher image 
intensity for a longer period of time than did the 7 mg/kg oral and the 500 
mg IV doses. The increased resolution of AOSLO FA, compared to 
conventional FA, offers great opportunity for studying physiological and 
pathological vascular processes. 
 
1 - Introduction  
 
Fluorescein angiography (FA) is the standard clinical tool for 
assessing retinal and choroidal vascular disease. Since its introduction 
in 1961 by Novotny and Alvis [1], its use has continued to grow, with 
more than 1.2 million public procedures reported in 2011 by Medicare 
[2]. FA reveals important pathological features of common vascular 
conditions including microaneurysms, vascular leakage, capillary non-
perfusion and neovascularization. In a variety of less common 
diseases, such as sickle cell retinopathy, hereditary macular diseases 
and retinal tumors, clinicians rely on FA to reveal characteristic 
patterns which help facilitate diagnosis and monitor treatment 
response [3].  
 
Despite its ubiquity in the modern eye care practice, intravenous 
(IV) FA is an invasive procedure and is associated with infrequent but 
potentially severe adverse reactions, and even rare anaphylactoid 
responses and death [4–8]. In order to acquire the early filling 
sequence, the photographer must image the eye within seconds 
following dye injection to capture its first appearance in the retinal 
vasculature. For diseases where early filling information is not critical, 
several investigators have demonstrated that oral administration of 
fluorescein allows a more extended imaging period [9–14]. Conditions 
as diverse as diabetic retinopathy, cystoid macular edema, central 
serous retinopathy and papilledema have been successfully imaged 
using oral fluorescein with comparable quality to IV fluorescein [9,11–
13,15–19]. Oral administration may be especially suitable for children 
and for patients with poor venous access [9,10,20]. More importantly, 
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side effects reported with oral administration of fluorescein have been 
fewer and milder [15,21], although isolated cases of anaphylactoid 
reactions have been reported [22,23].  
 
The ability to image the retinal microvasculature longitudinally 
in vivo is important for improving our understanding of physiological 
and pathological processes. It may also allow earlier recognition of 
pathology at stages where successful intervention may be possible and 
facilitate comparison of response to different treatment modalities. 
Conventional FA provides a wide-field view of the retinal vasculature, 
but its transverse and axial resolution is severely limited by ocular 
monochromatic aberrations. Histological comparisons have shown that 
fundus FA incompletely depicts the capillary networks [24]. Adaptive 
optics ophthalmoscopy has improved significantly over the past 
decade, enabling extraordinary microscopic views of retinal structures. 
Using the adaptive optics scanning light ophthalmoscope (AOSLO), in 
vivo studies of normal and pathological retinal microstructure have 
explored the photoreceptor mosaic [25,26], retinal pigment epithelium 
[27,28], nerve fiber layer [29] and microvasculature. More recently, 
motion contrast processing techniques applied to AOSLO have 
improved the visualization of retinal capillaries and micro-angiopathic 
features [30–33]. A variety of image processing methods that create 
image contrast from blood flow have also been applied to image sets 
acquired using retinal functional imager [34–36], optical coherence 
tomography (OCT) [37–42] and adaptive optics OCT [43] to visualize 
the retinal vasculature. Furthermore, additional non-invasive 
techniques have been successfully applied to imaging the retinal 
microvasculature including entoptic view [44–46] and adaptive optics 
flood-illumination [47,48]. Studies to demonstrate the clinical utility of 
these techniques are ongoing [41].  
 
Although the use of FA with the AOSLO has been demonstrated 
in primates [27,49] and rodents [50,51], it has not yet been explored 
in living human subjects. In this proof-of-concept manuscript, we 
report on the use of AOSLO FA for the in vivo visualization of normal 
human retinal microvasculature. We discuss imaging methodology, 
including instrument parameters, light safety, fluorescein dosage, 
fluorescein route of administration, and imaging window for sufficient 
fluorescence signal intensity.  
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2 - Methods  
 
2.1 Human subjects  
 
Ten subjects, 20 to 38 years of age (mean age 27, median age 
25) with no significant past medical or ocular histories were recruited. 
Written informed consent was obtained after the nature and potential 
risks of the procedure were explained. This study adhered to the 
tenets of the Declaration of Helsinki and was approved by the 
Institutional Review Board of the New York Eye and Ear Infirmary.  
 
2.2 Fluorescein  
 
Fluorescein came in 5 mL sterile vials containing 100 mg/mL 
fluorescein (AK-FLUOR 10%, Akorn, Inc., Lake Forest, Illinois). 
Previous authors have described various methods to make oral intake 
more palatable, including mixing the fluorescein with sugar [21], using 
encapsulated fluorescein pills [11,12,14,15] and mixing fluorescein 
with citrus juice [10,13]. For our experiments, oral fluorescein was 
administered with 50 mL of orange juice to mask its taste. The subject 
was instructed to drink the mixture rapidly, and the time of 
consumption was recorded as time zero. An additional 50 mL of orange 
juice was provided to wash out the residual taste of the fluorescein. In 
cases where IV administration of fluorescein was necessary, 
administration was performed by a nurse.  
 
For our experiments, the dose of fluorescein chosen was 
estimated to balance the risk of any adverse systemic effects of 
fluorescein with the estimated risk of retinal phototoxicity. For 
example, while a smaller dose of fluorescein reduces the risk of an 
adverse systemic reaction it produces a weaker fluorescence signal 
requiring more retinal exposure to the excitation light. Conversely, a 
larger dose of fluorescein carries a somewhat higher risk of adverse 
reaction but reduces the required exposure to light. With these 
requirements considered, a 20 mg fluorescein/kg body weight oral 
dose was chosen as the baseline fluorescein dose for all experiments. 
This dose is slightly lower than previously reported doses of 25 mg/kg 
or greater that gave adequate fluorescence intensity on FA 
[10,12,14,15].  
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From the ten subjects imaged, the first five subjects were used 
to gather preliminary data in optimizing the imaging protocol at 20 
mg/kg oral fluorescein. As described in Table 1, our results present 
data on the next five subjects in a series of five experiments using one 
subject each. Experiments 2-4 were designed to evaluate comparisons 
between fluorescein dosage, fluorescein route of administration, and 
imaging modality, and thus required two separate imaging sessions. 
Given that the half-life of fluorescein sodium is 267 minutes [52], 
subjects from Experiments 2-4 were given a minimum five days’ time 
between sessions to insure near total clearance of fluorescein from the 
body.  
 
2.3 Imaging protocol  
 
Axial length measurements were collected (IOL Master, Carl 
Zeiss Meditec AG, Jena, Germany) in order to calculate the AOSLO 
image scale in microns per pixel. Pixel size calculations were based on 
the Emsley schematic eye model [53]. Mydriasis and cycloplegia were 
induced with 1 drop each of 2.5% phenylephrine hydrochloride 
ophthalmic solution (Bausch&Lomb Inc., Tampa, FL) and 1% 
tropicamide ophthalmic solution (Akorn Inc., Lake Forest, IL). Color 
fundus photography (Topcon 3D OCT 2000, Topcon Corporation, 
Tokyo, Japan) was performed to provide clinical context to the retinal 
features seen with AOSLO imaging. Conventional scanning laser 
ophthalmoscope (SLO) FA (Heidelberg Spectralis HRA-OCT, Heidelberg 
Engineering Inc., Heidelberg, Germany) using oral fluorescein and FA 
(TRC 50IX Retinal Camera, Topcon Corporation, Tokyo, Japan) using 
IV fluorescein were performed for comparison with AOSLO FA (Table 
1). 
Stable and repeatable positioning of the subject’s eye during 
AOSLO imaging was achieved using a bite bar attached to a translation 
stage that allowed for fine transverse and axial adjustments. A dental 
impression material was used to stabilize the subject’s jaw on the bite 
bar (Splash! Putty, DenMat Holdings, LLC, Lompoc, California, USA). 
Transverse alignment of the subject was achieved by centering the 
pupil of the eye using the AOSLO wavefront sensor. Axial alignment 
was then achieved by maximizing the image intensity in the 
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reflectance channel and its uniformity across the field of view (FOV). 
Subjects were instructed to direct their gaze towards a green internal 
fixation target that was moved to allow imaging of specific locations of 
interest on the retina. During each imaging session, the reflectance 
channel was used to identify the regions of interest. Coordinates of 
these locations were recorded so that they could be re-imaged 
following fluorescein administration in the fluorescence channel. 
Optimal focus, determined for both the fluorescein excitation and 
reflectance channels, was recorded and used for all subsequent 
imaging of the identified locations.  
 
Previous studies have reported that maximum excitation signal 
intensity occurs 15-60 minutes following oral administration of 
fluorescein with visibility of pathologic features present up to 120 
minutes [9,11–15]. Given this information, AOSLO FA imaging 
sessions started at approximately 15 minutes post-administration of 
fluorescein in all experiments. In Experiments 3 and 4, AOSLO FA 
imaging began 15 minutes post-administration of fluorescein and 
continued at 20-minute intervals until 115 minutes had elapsed. 
During imaging, simultaneous segments of fluorescence and 
reflectance images consisting of 120-200 frames each were recorded 
at 15 frames per second using a 1°, 1.5° or 1.75° FOV. The gain of the 
detector in both channels was maintained at a constant level during all 
imaging sessions for all subjects. Throughout the imaging session, 
subjects were encouraged to blink frequently to support their normal 
tear film and were provided with short breaks of 3-5 minutes at 
regular intervals or as needed. 
2.4 AOSLO 
The AOSLO used for this study was a replica of the one by 
Dubra and Sulai [54], with the visible channel modified for 
fluorescence imaging. The modification involved replacement of the 
light source with a 488 nm diode laser (Lasos, Lasertechnick GmbH, 
Jena, Germany), and the addition of an interferometric band-pass 
optical filter centered at 525 nm with a 45 nm bandwidth in front of 
the detector. The longitudinal chromatic aberration (LCA) present in 
the human eye spreads the fluorescence focus along the optical axis 
over a range of approximately 0.3 diopters. This was addressed by 
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using a large (3.75 Airy disk diameter) confocal aperture. No attempt 
was made to account for LCA variation across individuals.  
 
Both the reflectance and fluorescence registered averaged 
images with high signal-to-noise ratio were generated by applying the 
frame-to-frame estimated eye motion calculated from the reflectance 
images, using sequences of 40-100 raw frames [27,55]. Typically, it 
took an examiner one minute to select 4-5 reference frames from each 
video, and it took an additional minute for the software to create the 
registered image averages. The registered image averages were then 
tiled (Adobe Photoshop CS6, Adobe Systems, Inc., San Jose, 
California, USA) to create larger fields of view.  
 
2.5 Light safety  
 
During AOSLO FA, the retina was simultaneously exposed to up 
to three different light sources (488, 790 and 850 nm), which entered 
the eye as superimposed (coaxial), near-collimated 7.75 mm diameter 
beams. All three beams localized onto a single spot on the fundus, 
which was rapidly scanned to form a 1.3, 1.95 or 2.3° square imaging 
raster, using a 14.5 KHz horizontal resonant optical scanner and a 16 
Hz vertical optical scanner. Synchronous modulation of the light 
sources turned them on at the start of the imaging portion of each 
horizontal line used for imaging when scanning from left to right. As a 
result only the central 1.0 to 1.75° of the scanning raster were 
exposed to light. The optical powers without modulation (i.e., 
continuous wave) measured at the cornea were 15 μW for the 850 nm 
wavefront sensing superluminescent diode (SLD), 100 μW for the 790 
nm imaging SLD and 32 μW for the 488 nm diode laser. During 
imaging, the on/off modulation reduced the average powers delivered 
to approximately 25% of their original values.  
 
No retinal location was exposed to the combined light sources 
for longer than 120 seconds. When immediately contiguous areas were 
imaged, the exposures were reduced to a maximum of 30 seconds to 
account for potential overlapping exposure of neighboring retinal 
locations due to involuntary eye motion. All sources were considered 
as lasers for the maximum permissible exposure (MPE) calculations, 
which were performed using the ANSI standard for the safe use of 
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lasers [56]. These imaging parameters, as described above, resulted 
in light exposures 6 times below both the photochemical and the 
thermal MPE limits.  
 
3 - Results  
 
In all 10 subjects, AOSLO FA was able to successfully resolve 
the smallest capillaries. Retinal vessels to the level of quaternary 
branches and capillary beds were clearly distinguishable from the rim 
of the optic disc to the foveal avascular zone (FAZ). Throughout the 
imaging session and during the six hours which followed, only one 
subject reported experiencing any adverse effects. The subject 
experienced transient nausea and heaving immediately following IV 
injection of fluorescein, which resolved shortly thereafter. As with 
conventional FA imaging, the intensity of the fluorescence in the 
AOSLO FA images varied over time, location and across individuals.  
 
3.1 Experiment 1: comparison of AOSLO FA vs. 
conventional SLO FA using oral fluorescein  
 
Images collected within 10 minutes of each other in a single 
subject using conventional scanning laser ophthalmoscope (SLO) FA 
and AOSLO FA, following oral administration of 20 mg/kg fluorescein, 
illustrate the superior resolution provided by the use of adaptive optics 
(Fig. 1). Numerous fine capillaries are revealed in the AOSLO FA 
images, which are not visible in the conventional SLO FA images. 
3.2 Experiment 2: comparison of AOSLO FA using oral 
fluorescein vs. conventional IV FA 
Conventional IV FA using a fundus camera was performed on a subject 
using 500 mg IV fluorescein. On a different visit, AOSLO FA images 
were collected, starting 15 minutes post-administration of oral (20 
mg/kg) fluorescein. 1.75° FOV AOSLO images were collected 
contiguously to complete a 6° box centered at the fovea. Comparison 
of the AOSLO FA montage with conventional IV FA shows that AOSLO 
FA reveals much finer vasculature with appreciably higher contrast 
(Fig. 2). 
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3.3 Experiment 3: comparison of oral versus IV 
fluorescein in AOSLO FA  
 
To assess the strength of the fluorescence signal as a function of 
time in oral versus IV administration, we imaged the same patient with 
AOSLO FA in two different imaging sessions. Oral fluorescein (20 
mg/kg) was used in the first session, and IV fluorescein (500 mg) was 
used in the second session. AOSLO imaging began 15 minutes post-
administration of fluorescein and continued at 20-minute intervals until 
115 minutes had elapsed (Fig. 3). The mean pixel value of the 
resulting images was used as a metric for fluorescence signal. As 
shown in Fig. 3, oral and IV fluorescein provided similar image 
intensities at 17 minutes and 18 minutes after administration 
respectively. At 35 minutes or more after administration, oral 
fluorescein provided higher peak image intensity and more sustained 
fluorescence compared to IV fluorescein. It should be noted that peak 
intensity in the case of IV administration probably occurred before the 
first image of the sequence. 
3.4 Experiment 4: AOSLO FA oral fluorescein dosimetry  
 
In an effort to minimize potential adverse reactions to orally 
administered fluorescein, we explored the feasibility of visualizing 
retinal vasculature using a lower dose (7 mg/kg vs. 20 mg/kg). Figure 
4 shows images from one area of interest that was imaged at both the 
high and low dose of fluorescein in two separate imaging sessions. As 
previously described, AOSLO imaging began 15 minutes post-
administration of fluorescein and continued at 20-minute intervals until 
115 minutes had elapsed. Similarly, the mean pixel value of the 
resulting images was used as a metric for fluorescence signal. The 
sequence of images shown in Fig. 4 demonstrate that comparable 
images were produced by both doses, although as expected, the 
fluorescence signal, as measured by the mean pixel values, scaled 
with the dose. Both doses, however, appear sufficient in most cases to 
allow for AOSLO FA imaging for as long as an hour, although this could 
vary significantly across visits and individuals.  
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Biomedical Optics Express, Vol. 4, No. 8 (August 2013): pg. 1305-1317. DOI. This article is © Optical Society of America 
and permission has been granted for this version to appear in e-Publications@Marquette. Optical Society of America 
does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express 
permission from Optical Society of America. 
11 
 
3.5 Experiment 5: resolution of overlying peripapillary 
capillary beds using AOSLO FA  
 
We examined the ability of AOSLO FA to axially resolve 
overlying capillary beds at 4 peripapillary locations (Fig. 5(A) insets B, 
C, D and E) using 20 mg/kg oral fluorescein. AOSLO FA was able to 
resolve the radial peripapillary capillary bed (Fig. 5(B2), 5(C2), 5(D2) 
and 5(E2)) within the highly reflective surface of the nerve fiber layer 
(Fig. 5(B1), (C1), (D1) and (E1)). As the focus shifted toward the 
outer retina, deeper capillary beds were resolved (Fig. 5(B3), 5(C3), 
5(D3) and 5(E3)). Images of the deeper capillary beds appear 
somewhat noisier due to background haze from the out-of-focus 
fluorescence signal of the choroidal vasculature. 
4 - Discussion  
 
We have demonstrated that AOSLO FA can reveal microscopic 
detail of the retinal vasculature at safe light exposures in human 
subjects using oral or IV fluorescein. With both methods of fluorescein 
administration, AOSLO FA was able to visualize the retinal capillary 
beds at all attempted retinal locations and at multiple depths with 
qualitatively comparable contrast and sharpness. While both the 7 
mg/kg oral dose and 500 mg IV dose successfully visualized the fine 
capillaries, the 20 mg/kg dose provided a stronger, more sustained 
fluorescence signal. Thus, 20 mg/kg oral administration of fluorescein 
seems more suitable for surveying larger retinal areas, given the 
current limited FOV (typically < 3°) of the AOSLO. It is important to 
note that, compared to conventional FA, the small FOV of the AOSLO 
limits its ability to acquire the early filling sequence of fluorescein over 
a large retinal area. Fluorescence peak and disappearance varied both 
across individuals and visits with both oral and IV fluorescein. Even 
with this variability, we were able to achieve up to an hour of sufficient 
signal intensity when using 20 mg/kg oral fluorescein.  
 
Consistent with previous reports [15,21], adverse reactions to 
fluorescein occurred less frequently when administered orally. Only 
one adverse reaction (nausea and heaving) occurred following IV 
administration in this series, with none following oral administration. 
Since isolated case reports have described rare but occasionally severe 
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reactions to orally administered fluorescein, it is very important to 
elicit any patient history of atopy or past reactions to fluorescein [57]. 
Precautionary measures in the imaging laboratory such as ready 
access to a resuscitative crash cart are also recommended [5].  
 
Currently, AOSLO FA appears to offer reasonable signal-to-noise 
ratio, no image processing artifacts, axial sectioning, and near-
diffraction-limited transverse and axial resolution. For an average eye 
with effective focal length of approximately 17 mm and a pupil 
diameter of 7.75 mm, AOSLO FA approaches an axial resolving limit of 
20 μm, enabling it to resolve overlying capillary beds in the retina 
[58]. However, a significant clinical limitation of AOSLO FA which must 
be considered is that the potential transverse and axial resolution of 
the AOSLO can only fully materialize with unobstructed large pupils. 
Lower reflectance and fluorescence signal and/or poorer resolution 
should be expected in subjects with small pupils and/or cataracts. 
AOSLO image quality can also be affected by non-clear media, retinal 
or anterior chamber inflammation and multifocal or diffractive 
intraocular lens implants. Imaging the vasculature with conventional 
(i.e., non-AO) OCT-based techniques, on the other hand, may be less 
affected by cataracts because they do not require a large pupil, 
although lower transverse resolution is to be expected. We believe that 
new and developing microvascular imaging technologies, including 
non-invasive motion contrast image processing techniques [34,35,37–
39,43], will prove to be synergistic with AOSLO FA and perhaps better 
suited for fast non-invasive screening. Further studies are necessary to 
determine the full advantages and limitations of these emerging 
technologies relative to each other. AOSLO FA, although not likely to 
replace conventional wide-field FA, offers great potential for studying 
and quantifying retinal microvascular attributes such as vessel 
diameter, branching pattern, tortuosity and capillary density in both 
healthy and disease states. Much can be learned by applying already 
developed metrics and geometrical descriptors for retinal and brain 
vascular imaging [59–64]. Coupled with methods to quantify 
microvascular attributes, we believe that AOSLO FA will provide 
insights into retinal vascular diseases, and has the potential to become 
a clinical tool in detecting disease, disease progression, and tissue 
response to traditional and emerging treatment modalities. 
Furthermore, through studying and characterizing the retinal 
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microvascular changes that occur in systemic cardiovascular disease 
with AOSLO FA, we can potentially gain a deeper understanding of 
pathological processes and end-organ damage that occur in diabetes, 
hypertension and vascular occlusion [65,66].  
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Table 1. AOSLO FA Experiments 
 
Description of fluorescein dosages, routes of administration and imaging 
modalities used during imaging sessions in Experiments 1-5. Experiments 1 
and 5 consisted of a single imaging session. 
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Fig. 1. Conventional SLO FA image (A) taken 20 minutes after oral 
administration of 20 mg/kg fluorescein, with two areas of interest (A insets B 
and C) approximately 5° from the fovea. These same areas were magnified 
and contrast stretched (B1 and C1) for comparison with AOSLO FA images of 
the corresponding areas (B2 and C2), collected 30 minutes after oral 
fluorescein administration. The scale bar represents 100 μm and applies to all 
images other than image A. 
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Fig. 2. Conventional IV FA image of the FAZ was magnified and contrast 
stretched (A) for comparison with an AOSLO FA image montage of the same 
region (B). The AOSLO scale bar represents 500 μm. 
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Fig. 3. Comparison of AOSLO FA image sequences after oral or IV fluorescein 
administration, showing a retinal area approximately 5° inferotemporal from 
the fovea. Fluorescein was administered at time zero. Mean pixel value was 
calculated for each image and then normalized to the maximum value of the 
oral and IV image series to generate the intensity percentages, presented on 
the top right corner of each image. All images were then contrast stretched to 
make optimal use of the gray scale while avoiding saturation. The contrast-
stretched images are presented in this figure. The scale bar represents 100 
μm. 
 
Fig. 4. Comparison of AOSLO FA image sequences between 20 mg/kg and 7 
mg/kg oral administration of fluorescein, showing a retinal area 
approximately 5° superior-nasal from the fovea. Mean pixel values were 
calculated for each image and then normalized to the maximum value of the 
oral and IV image series to generate the intensity percentages, presented on 
the top right corner of each image. All images were then contrast stretched to 
make optimal use of the gray scale while avoiding saturation. The contrast-
stretched images are presented in this figure. The scale bar represents 100 
μm. 
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Fig. 5. Conventional SLO FA image acquired approximately 30 minutes after 
oral fluorescein administration (A) showing four peripapillary locations chosen 
for AOSLO imaging (A insets B, C, D and E). The reflectance AOSLO images of 
these small areas, focused on the nerve fiber layer (B1, C1, D1 and E1), show 
large blood vessels, capillaries and nerve fiber bundles. The corresponding 
AOSLO FA images recorded at the same focus (B2, C2, D2 and E2) 
approximately 15 minutes after oral fluorescein administration show only 
vasculature, revealing the radial peripapillary capillary bed with high contrast 
and detail. Peripapillary capillaries (B2, C2, D2 and E2) can be seen radiating 
parallel to the nerve fibers (B1, C1, D1 and E1). Capillary free zones can be 
seen surrounding arteries (B2, C2 and lower E2) and not veins (D2 and upper 
E2). AOSLO FA images focused closer to the outer retina (B3, C3, D3 and E3) 
show additional non-radial capillaries (arrow heads). These retinal capillaries 
can be seen deriving from the same retinal arteries (arrows) that supply the 
peripapillary capillaries. The scale bar represents 100 μm and applies to all 
images other than image A. 
 
